8.11
price up icon7.85%   0.59
after-market Handel nachbörslich: 8.12 0.010 +0.12%
loading
Schlusskurs vom Vortag:
$7.52
Offen:
$7.52
24-Stunden-Volumen:
298.95K
Relative Volume:
0.78
Marktkapitalisierung:
$478.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.1978
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+8.86%
1M Leistung:
+5.74%
6M Leistung:
-22.84%
1J Leistung:
-57.54%
1-Tages-Spanne:
Value
$7.42
$8.19
1-Wochen-Bereich:
Value
$7.42
$8.19
52-Wochen-Spanne:
Value
$6.85
$21.01

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
Firmenname
Cullinan Therapeutics Inc
Name
Telefon
617-410-4650
Name
Adresse
ONE MAIN STREET, CAMBRIDGE
Name
Mitarbeiter
111
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CGEM's Discussions on Twitter

Vergleichen Sie CGEM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CGEM
Cullinan Therapeutics Inc
8.11 439.66M 0 -153.16M -134.48M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-11 Fortgesetzt Stifel Buy
2024-10-24 Eingeleitet UBS Buy
2024-05-01 Eingeleitet Stifel Buy
2024-04-15 Eingeleitet William Blair Outperform
2024-02-15 Eingeleitet Wedbush Outperform
2023-06-15 Eingeleitet TD Cowen Outperform
2022-11-21 Eingeleitet BTIG Research Buy
2021-04-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-02-02 Eingeleitet Evercore ISI Outperform
2021-02-02 Eingeleitet Morgan Stanley Equal-Weight
2021-02-02 Eingeleitet SVB Leerink Outperform
2021-02-01 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Cullinan Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan

Jul 22, 2025
pulisher
Jul 20, 2025

Is Cullinan Therapeutics Inc. a good long term investmentFree Predictions - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Cullinan Therapeutics Inc. stockExplosive market performance - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Cullinan Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Disc Medicine Appoints Nadim Ahmed To Board - citybiz

Jul 14, 2025
pulisher
Jul 14, 2025

Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times

Jul 14, 2025
pulisher
Jul 10, 2025

We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jul 09, 2025
pulisher
Jul 03, 2025

Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia

Jul 03, 2025
pulisher
Jun 30, 2025

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 21, 2025

Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 21, 2025
pulisher
Jun 20, 2025

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com

Jun 20, 2025
pulisher
Jun 17, 2025

Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World

Jun 17, 2025
pulisher
Jun 12, 2025

Cullinan Management Holds Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech

Jun 12, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

The week in pharma: action, reaction and insight – week to June 6 - The Pharma Letter

Jun 08, 2025
pulisher
Jun 07, 2025

Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus

Jun 04, 2025

Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):